2026-05-10T16:24:46Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/235182024-11-28T17:38:20Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16961col_20.500.12105_16967col_20.500.12105_16984col_20.500.12105_16985
Repisalud
author
Barretina-Ginesta, Maria Pilar
author
Quindós, María
author
Alarcón Company, Jesús
author
Esteban, Carmen
author
Gaba Garcia, Lydia
author
Gomez, Cesar
author
Perez Fidalgo, Jose Alejandro
author
Romero, Ignacio
author
Santaballa, Ana
author
Rubio-Perez, Maria Jesús
2024-10-04T13:57:55Z
2024-10-04T13:57:55Z
2022-04
Barretina-Ginesta MP, Quindos M, Alarcon JD, Esteban C, Gaba L, Gomez C, et al. SEOM-GEICO clinical guidelines on endometrial cancer (2021). Clin Transl Oncol. 2022 Apr;24(4):625-34.
10.1007/s12094-022-02799-7
1699-3055
1699-048X
Clinical & Translational Oncology
https://hdl.handle.net/20.500.13003/19815
35312947
L2015382411
2-s2.0-85126803367
https://hdl.handle.net/20.500.12105/23518
771319500001
Endometrial cancer (EC) is the second most common gynecological malignancy worldwide, the first in developed countries [Sung et al. in CA Cancer J Clin 71:209-249, 2021]. Although a majority is diagnosed at an early stage with a low risk of relapse, an important proportion of patients will relapse. Better knowledge of molecular abnormalities is crucial to identify high-risk groups in early stages as well as for recurrent or metastatic disease for whom adjuvant treatment must be personalized. The objective of this guide is to summarize the current evidence for the diagnosis, treatment, and follow-up of EC, and to provide evidence-based recommendations for clinical practice.
eng
Endometrial cancer
Guideline
Diagnosis
Treatment
SEOM-GEICO clinical guidelines on endometrial cancer (2021)
research article